These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 27160418)

  • 21. Isavuconazonium sulfate (Cresemba)--a new antifungal.
    Med Lett Drugs Ther; 2016 Mar; 58(1490):37-8. PubMed ID: 26963156
    [No Abstract]   [Full Text] [Related]  

  • 22. New pharmacological opportunities for the treatment of invasive mould diseases.
    Ledoux MP; Toussaint E; Denis J; Herbrecht R
    J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i48-i58. PubMed ID: 28355467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options.
    Riley TT; Muzny CA; Swiatlo E; Legendre DP
    Ann Pharmacother; 2016 Sep; 50(9):747-57. PubMed ID: 27307416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.
    Floros L; Kuessner D; Posthumus J; Bagshaw E; Sjölin J
    BMC Infect Dis; 2019 Feb; 19(1):134. PubMed ID: 30744563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Invasive aspergillosis in solid organ transplantation].
    Silva JT; Torre-Cisneros J; Aguado JM
    Rev Iberoam Micol; 2018; 35(4):206-209. PubMed ID: 30467000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-life use of isavuconazole outside the hematological wards.
    Scabini S; Lupia T; Angilletta R; De Rosa FG; Corcione S
    Eur J Intern Med; 2019 Dec; 70():e10-e12. PubMed ID: 31526649
    [No Abstract]   [Full Text] [Related]  

  • 27. Isavuconazole: A New Option for the Management of Invasive Fungal Infections.
    Pettit NN; Carver PL
    Ann Pharmacother; 2015 Jul; 49(7):825-42. PubMed ID: 25940222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Invasive mould infections in the ICU setting: complexities and solutions.
    Bassetti M; Bouza E
    J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i39-i47. PubMed ID: 28355466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis.
    Cheng MP; Orejas JL; Arbona-Haddad E; Bold TD; Solomon IH; Chen K; Pandit A; Kusztos AE; Cummins KC; Liakos A; Marty FM; Koo S; Hammond SP
    Mycoses; 2020 Jan; 63(1):58-64. PubMed ID: 31587405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi.
    Desai A; Kovanda L; Kowalski D; Lu Q; Townsend R; Bonate PL
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5483-91. PubMed ID: 27381396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi.
    Desai AV; Kovanda LL; Hope WW; Andes D; Mouton JW; Kowalski DL; Townsend RW; Mujais S; Bonate PL
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Isavuconazole-induced Acute Liver Failure in a Pediatric Patient With Invasive Aspergillosis.
    Brivio E; Verna M; Migliorino GM; Foresti S; Zucchini N; Rovelli A
    Pediatr Infect Dis J; 2019 Oct; 38(10):1035-1037. PubMed ID: 31568141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isavuconazole Treatment of Invasive Fungal Sinusitis: A Post Hoc Analysis of the SECURE and VITAL Trials.
    Durand ML; Kitt TM; Song Y; Marty FM
    Clin Infect Dis; 2021 Sep; 73(6):e1380-e1383. PubMed ID: 33914864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Current therapeutic options in invasive mycosis and potential therapeutic role of isavuconazole].
    Garcia-Vidal C
    Rev Iberoam Micol; 2018; 35(4):192-197. PubMed ID: 30455108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How We Approach Combination Antifungal Therapy for Invasive Aspergillosis and Mucormycosis in Transplant Recipients.
    Haidar G; Singh N
    Transplantation; 2018 Nov; 102(11):1815-1823. PubMed ID: 29975240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Isavuconazole shortens the QTc interval.
    Mellinghoff SC; Bassetti M; Dörfel D; Hagel S; Lehners N; Plis A; Schalk E; Vena A; Cornely OA
    Mycoses; 2018 Apr; 61(4):256-260. PubMed ID: 29178247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against Aspergillus spp. and 2 rare moulds.
    Pfaller MA; Rhomberg PR; Castanheira M
    Diagn Microbiol Infect Dis; 2018 Sep; 92(1):43-45. PubMed ID: 29735424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment Failure of Isavuconazole in a Patient with Cryptococcosis.
    Linder KA; Gandhi TN; Miceli MH
    Mycopathologia; 2019 Oct; 184(5):667-670. PubMed ID: 31451965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical experience with isavuconazole in healthy volunteers and patients with invasive aspergillosis in China, and the results from an exposure-response analysis.
    Zhang J; Zhang Y; Wu D; Cao G; Hamed K; Desai A; Aram JA; Guo X; Fayyad R; Cornely OA
    Mycoses; 2021 Apr; 64(4):445-456. PubMed ID: 33355949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib.
    Cummins KC; Cheng MP; Kubiak DW; Davids MS; Marty FM; Issa NC
    Leuk Lymphoma; 2019 Feb; 60(2):527-530. PubMed ID: 30037292
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.